Cited by 174IL-33, ST2, and ILC PathwaysInflammasome and immune disordersTelomeres, Telomerase, and Senescence

Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma

Open access
Yamagishi, Ryota, Kamachi, Fumitaka, Nakamura, Masaru, Yamazaki, Shota, Kamiya, Tomonori, Takasugi, Masaki, Cheng, Yi, Nonaka, Yoshiki +21 more·2022·Science Immunology

Abstract

Long-term senescent cells exhibit a secretome termed the senescence-associated secretory phenotype (SASP). Although the mechanisms of SASP factor induction have been intensively studied, the release mechanism and how SASP factors influence tumorigenesis in the biological context remain unclear. In this study, using a mouse model of obesity-induced hepatocellular carcinoma (HCC), we identified the release mechanism of SASP factors, which include interleukin-1β (IL-1β)– and IL-1β–dependent IL-33, from senescent hepatic stellate cells (HSCs) via gasdermin D (GSDMD) amino-terminal–mediated pore. We found that IL-33 was highly induced in senescent HSCs in an IL-1β–dependent manner in the tumor microenvironment. The release of both IL-33 and IL-1β was triggered by lipoteichoic acid (LTA), a cell wall component of gut microbiota that was transferred and accumulated in the liver tissue of high-fat diet–fed mice, and the release of these factors was mediated through cell membrane pores formed by the GSDMD amino terminus, which was cleaved by LTA-induced caspase-11. We demonstrated that IL-33 release from HSCs promoted HCC development via the activation of ST2-positive T reg cells in the liver tumor microenvironment. The accumulation of GSDMD amino terminus was also detected in HSCs from human NASH-associated HCC patients, suggesting that similar mechanism could be involved in a certain type of human HCC. These results uncover a release mechanism for SASP factors from sensitized senescent HSCs in the tumor microenvironment, thereby facilitating obesity-associated HCC progression. Furthermore, our findings highlight the therapeutic potential of inhibitors of GSDMD-mediated pore formation for HCC treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciimmunol.abl7209

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • p21 increased with age in a subset of terminally differentiated myofibers, which also displayed other senescence-associated markers such as TAF, SADS, nuclear loss of LMNB1, HMGB1, and a unique SASP.

    “Interestingly, p21 increased with age in a subset of terminally differentiated myofibers, which also displayed other senescence-associated markers such as TAF, SADS, nuclear loss of LMNB1, HMGB1, and a unique SASP88,89.”

    From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [89]

    The section ‘IL-33 from senescent HSCs promotes obesity-associated HCC development’ reports more p21-positive hepatic stellate cells in high-fat-diet mouse livers, alongside SASP factors. It does not report an age-related increase in p21 in terminally differentiated myofibers or the listed markers in those cells (searched: myofibers, skeletal muscle, TAF, SADS, and HMGB1). (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yamagishi, R., Kamachi, F., Nakamura, M., Yamazaki, S., Kamiya, T., Takasugi, M., Cheng, Y., Nonaka, Y., Yukawa-Muto, Y., Thuy, L. T. T., Harada, Y., Arai, T., Loo, T. M., Yoshimoto, S., Ando, T., Nakajima, M., Taguchi, H., Ishikawa, T., Akiba, H., Miyake, S., Kubo, M., Iwakura, Y., Fukuda, S., Chen, W.-Y., Kawada, N., Rudensky, A., Nakae, S., Hara, E., & Ohtani, N.
Affiliations
  • Osaka City University (JP)
  • Tokyo University of Science (JP)
  • Department of Pathophysiology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).
  • Department of Hepatology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).
  • Japanese Foundation For Cancer Research (JP)
  • Institute for Advanced Biosciences, Keio University (JP)
  • Juntendo University (JP)
  • University of Tsukuba (JP)
  • Kaohsiung Chang Gung Memorial Hospital (TW)
  • Memorial Sloan Kettering Cancer Center (US)
  • Hiroshima University (JP)
  • Center for Infectious Disease Education and Research, The University of Osaka (JP)
Corresponding author
  • Yamagishi, Ryota
  • Kamachi, Fumitaka
  • Ohtani, Naoko
Venue
Science Immunology
Published
2022-06-24
Volume
7
Issue
72
Pages
eabl7209-eabl7209
ISSN
2470-9468 (ISSN-L)
OpenAlex
W4283362074
Cited by
173
References
63
Citations by year
2026: 36 · 2025: 48 · 2024: 54 · 2023: 30 · 2022: 5
FWCI
13.09
Type
journal article
Language
en
Open access
Locations
  • Science Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
  • Osaka City University (Osaka City University) (submittedVersion)
Funders
  • Japan Agency for Medical Research and Development (JP20gm1010009, JP20gm5010001)
  • Princess Takamatsu Cancer Research Fund (18‐25003)
  • Yakult Bio-Science Foundation
  • Japan Society for the Promotion of Science (21H02964, 20H03176, 25003, 23K24322, 22K08083, 19H04002, 19H03641, 20K15695, 18H02847, 20K16121, 20K16309, 21H02963, 22H00457)
  • Japan Science and Technology Agency (JPMJPR18H6, JPMJFS 2138, JPMJER1902)
  • Core Research for Evolutional Science and Technology (JP20gm1010009, JP20gm5010001)
  • Precursory Research for Embryonic Science and Technology (JPMJPR18H6)
  • Exploratory Research for Advanced Technology (JPMJER1902)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
Keywords
gasdermin D, senescence-associated secretory phenotype, hepatic stellate cells, IL-1β, lipoteichoic acid, caspase-11, tumor microenvironment, high-fat diet, gut microbiota
MeSH terms
Interleukin-33, Gasdermins, Animals, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Obesity, Cellular Senescence, Phosphate-Binding Proteins, Mice, Pore Forming Cytotoxic Proteins, Hepatic Stellate Cells, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review